RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Sino Biopharmaceutical Stock

Sino Biopharmaceutical Equity 2024

Sino Biopharmaceutical Equity

30.47 B CNY

Ticker

1177.HK

ISIN

KYG8167W1380

WKN

A0CBDJ

In 2024, Sino Biopharmaceutical's equity was 30.47 B CNY, a 2.45% increase from the 29.75 B CNY equity in the previous year.

Sino Biopharmaceutical Aktienanalyse

What does Sino Biopharmaceutical do?

Sino Biopharmaceutical Ltd is a leading biopharmaceutical company in China that focuses on research, development, production, and distribution of medications. The company is headquartered in Hong Kong and is listed on the Hong Kong Stock Exchange. The company was founded in 2000 by Dr. Tse Ping, an experienced entrepreneur in the chemical industry. The goal was to develop innovative medications that could improve people's health and lives. Since then, Sino Biopharmaceutical has become a major player in the pharmaceutical industry. Sino Biopharmaceutical's business model is based on three pillars: generics, innovative medications, and contract manufacturing. The company specializes in the development and production of generics to make affordable, high-quality medications accessible to the masses. At the same time, the company also invests in research and development of innovative medications for rare and serious diseases. Additionally, Sino Biopharmaceutical also offers contract manufacturing services to other companies. Sino Biopharmaceutical operates in four divisions: pharmaceutical manufacturing, research and development of biopharmaceutical medications, contract manufacturing, and sales and marketing activities. Pharmaceutical manufacturing includes the production of generics as well as the manufacturing of medications for specific indications. Research and development of biopharmaceutical medications focuses on the development of therapies for severe and rare diseases. Contract manufacturing involves the manufacturing process from raw material sourcing to packaging medications for other companies. Sales and marketing activities involve positioning and promoting Sino Biopharmaceutical's products in the market. Some of Sino Biopharmaceutical's well-known products include Hengrui Medicine, an anticancer medication used to treat cancer; Yigu, a medication for liver diseases; and Tongbi, a medication for osteoporosis. Sino Biopharmaceutical has a strong presence in the Chinese market, as well as the international market. The company exports its products to over 60 countries worldwide. Sino Biopharmaceutical has also become a key partner for international companies and regularly collaborates with other pharmaceutical corporations to expand their expertise in product development and manufacturing. In summary, Sino Biopharmaceutical Ltd is a major player in the pharmaceutical industry that specializes in the development and production of generics and innovative medications. There is also a focus on contract manufacturing of medications for other companies. The company has a strong presence in the Chinese market and exports its products to over 60 countries. Sino Biopharmaceutical ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Sino Biopharmaceutical's Equity

Sino Biopharmaceutical's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Sino Biopharmaceutical's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Sino Biopharmaceutical's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Sino Biopharmaceutical's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Sino Biopharmaceutical’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Sino Biopharmaceutical stock

What is the equity of Sino Biopharmaceutical this year?

Sino Biopharmaceutical has equity of 30.47 B CNY this year.

What was the equity of Sino Biopharmaceutical compared to the previous year?

The equity of Sino Biopharmaceutical has increased/decreased by 2.45% increased compared to the previous year.

What impact does a high equity have on investors of Sino Biopharmaceutical?

A high equity is advantageous for investors of Sino Biopharmaceutical as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Sino Biopharmaceutical?

A low equity can be a risk for investors of Sino Biopharmaceutical, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Sino Biopharmaceutical affect the company?

An increase in equity of Sino Biopharmaceutical can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Sino Biopharmaceutical affect the company?

A reduction in equity of Sino Biopharmaceutical can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Sino Biopharmaceutical?

Some factors that can affect the equity of Sino Biopharmaceutical include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Sino Biopharmaceutical so important for investors?

The equity of Sino Biopharmaceutical is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Sino Biopharmaceutical take to change the equity?

To change equity, Sino Biopharmaceutical can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Sino Biopharmaceutical pay?

Over the past 12 months, Sino Biopharmaceutical paid a dividend of 0.08 CNY . This corresponds to a dividend yield of about 2.13 %. For the coming 12 months, Sino Biopharmaceutical is expected to pay a dividend of 0.08 CNY.

What is the dividend yield of Sino Biopharmaceutical?

The current dividend yield of Sino Biopharmaceutical is 2.13 %.

When does Sino Biopharmaceutical pay dividends?

Sino Biopharmaceutical pays a quarterly dividend. This is distributed in the months of November, July, October, October.

How secure is the dividend of Sino Biopharmaceutical?

Sino Biopharmaceutical paid dividends every year for the past 26 years.

What is the dividend of Sino Biopharmaceutical?

For the upcoming 12 months, dividends amounting to 0.08 CNY are expected. This corresponds to a dividend yield of 2.22 %.

In which sector is Sino Biopharmaceutical located?

Sino Biopharmaceutical is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sino Biopharmaceutical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sino Biopharmaceutical from 10/4/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 9/12/2024.

When did Sino Biopharmaceutical pay the last dividend?

The last dividend was paid out on 10/4/2024.

What was the dividend of Sino Biopharmaceutical in the year 2023?

In the year 2023, Sino Biopharmaceutical distributed 0.1 CNY as dividends.

In which currency does Sino Biopharmaceutical pay out the dividend?

The dividends of Sino Biopharmaceutical are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Sino Biopharmaceutical

Our stock analysis for Sino Biopharmaceutical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sino Biopharmaceutical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.